Prostate Cancer Metastasis Prediction Using Stromal Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools to predict prostate cancer metastasis, necessitating new approaches to assess the aggressiveness of prostate cancer and determine appropriate treatment strategies.
Innovation Solution
A method evaluating the expression of 8 specific genes (NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1, and GALNT16) in prostate stromal cells to predict metastasis, using techniques like microarrays and RT-PCR to determine gene expression patterns, distinguishing between benign, non-metastatic, and metastatic cancer samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If no specific predictive tools are used, then treatment decisions are made without precise metastasis risk assessment, but the ability to predict metastasis and guide timely intervention is improved by implementing gene expression analysis
Solution Approach 1:
The diagnostic method is segmented into a specific panel of 8 genes (NRP1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1, GALNT16) rather than analyzing all genes. This segmentation makes the complex task of metastasis prediction manageable and clinically implementable while maintaining high accuracy in distinguishing metastatic from non-metastatic prostate cancer cases.
Solution Approach 2:
The invention changes the parameter being measured from general tumor characteristics to specific gene expression levels in stromal cells. By focusing on expression levels of these 8 particular genes rather than broad tumor markers, the method achieves precise metastasis prediction through quantifiable molecular parameters that can be reliably measured and compared.
2Reliability
If gene expression analysis of 8 specific genes is performed, then metastasis prediction accuracy is improved, but the complexity of the diagnostic procedure increases
Solution Approach 1:
The 8-gene signature serves multiple functions: it predicts metastasis risk, guides treatment intensity decisions, and can be applied to various prostate cancer cases regardless of other clinical variables. This multi-functionality increases reliability while the standardized gene panel keeps the procedural complexity manageable through reuse of the same analytical framework.
Solution Approach 2:
The method uses standardized gene expression profiles as reference copies to compare against patient samples. By establishing baseline expression patterns for these 8 genes in metastatic versus non-metastatic cases, the system creates reproducible reference data that enhances prediction reliability without requiring complex real-time analysis for each new patient.
3Difficulty of detecting and measuring
If stromal cell gene expression is evaluated, then the ability to detect metastatic potential is improved, but the difficulty of sample analysis increases
Solution Approach 1:
The method extracts and isolates stromal cells from the tumor tissue sample, separating them from epithelial and other cell types. This extraction focuses the analysis specifically on the stromal compartment where the 8 key genes are differentially expressed, making detection of metastatic potential more straightforward while reducing the complexity of analyzing mixed tissue samples.
Solution Approach 2:
The stromal cells act as an intermediary that reflects the metastatic potential of the tumor. Rather than directly analyzing tumor cells which may be heterogeneous and difficult to interpret, the method uses stromal cell gene expression as an intermediary marker that reliably indicates metastatic risk, simplifying the detection process while maintaining accuracy.
Data Source
Figure 1~2-1
Figure 2-2~2-3
Figure 2-4~2-5
AI summary
Ex vivo method for the prognosis of metastasis in prostate cancer which comprises determining the level of expression of at least one of the following genes: NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 and GALNT16, in a biological sample that contains stromal cells of a prostate cancer primary tumor; and establish whether the expression of the genes NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 is increased or if the expression of the GALNT16 gene is diminished, which correlates with the prognosis of metastasis in prostate cancer. And a kit for predicting metastases in prostate cancer comprising means for quantifying the products of the genes NRP-1, MFAP4, NRIP3, THBS2, TNF, EDN1, EBF1 and GALNT16, in a sample comprising prostatic stromal cells.